Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1 3Phase EARLY_PHASE1 2Phase 1/2 2Phase 3 1

Status

Completed 22Recruiting 21Unknown 16Active not recruiting 16Terminated 11Withdrawn 8Not yet recruiting 2

Sponsor Class

OTHER 6INDUSTRY 2

Study Type

Interventional 8

Sponsor

Cancer Type

Gastrointestinal 3Genitourinary 2Sarcoma 1Other solid neoplasm 1Lymphoid 1Gynecologic 1

Conditions

Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 1MMR-D/MSI-H Colorectal Cancers 1Lymphoma 1Leiomyosarcoma 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1

Interventions

pembrolizumab 61Radiotherapy 55Gemcitabine 51Paclitaxel 49Cyclophosphamide 48Cisplatin 48Carboplatin 45Dexamethasone 37Bevacizumab 37Nivolumab 35Fluorouracil 34Docetaxel 34Oxaliplatin 33durvalumab 32Rituximab 28Magnetic Resonance Spectroscopy 28Leucovorin 28Drug Therapy 25Pemetrexed 24Doxorubicin 24Capecitabine 24atezolizumab 22Radiation 20Cytarabine 20Radiosurgery 19Prednisone 19Etoposide 19Irinotecan 17Bortezomib 17Cetuximab 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

8 trials
RecentStart dateEnrollment
Phase 2 × Withdrawn × niraparib × Clear all
NCT06392841 2026-04-08

HARMONY

Hoosier Cancer Research Network

Phase 2 Withdrawn
Genitourinary

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT06527690 2025-09-29

REPRESENTATION

Latin American Cooperative Oncology Group

Phase 2 Withdrawn
Genitourinary

Prostatic Neoplasms

NCT05126342 2025-04-06

Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi

AGO Research GmbH

Phase 2 Withdrawn
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06365970 2025-02-03

Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers

University of Pittsburgh

Phase 2 Withdrawn
GastrointestinalOther solid neoplasm

MMR-D/MSI-H Colorectal Cancers

NCT05174455 2023-09-18

Niraparib for the Treatment of Leiomyosarcoma

Ohio State University Comprehensive Cancer Center

Phase 2 Withdrawn
Sarcoma

Leiomyosarcoma

NCT05412706 2023-09-08

Bohème

Ospedale Policlinico San Martino

Phase 2 Withdrawn
Gastrointestinal

Colorectal Neoplasms

NCT04895046 2022-06-29

Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma

Hoosier Cancer Research Network

Phase 2 Withdrawn
Gastrointestinal

Neoplasm Metastasis, Cholangiocarcinoma

NCT01244009 2016-11-07

A Study of MK-4827 for the Treatment of Mantle Cell Lymphoma (MK-4827-002)

Tesaro, Inc.

Phase 2 Withdrawn
Lymphoid

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡